Atea Pharmaceuticals (AVIR) Free Cash Flow (2020 - 2022)
Historic Free Cash Flow for Atea Pharmaceuticals (AVIR) over the last 3 years, with Q4 2022 value amounting to -$21.5 million.
- Atea Pharmaceuticals' Free Cash Flow rose 7143.44% to -$21.5 million in Q4 2022 from the same period last year, while for Dec 2022 it was -$122.9 million, marking a year-over-year decrease of 4128.5%. This contributed to the annual value of -$135.5 million for FY2024, which is 5867.32% down from last year.
- Per Atea Pharmaceuticals' latest filing, its Free Cash Flow stood at -$21.5 million for Q4 2022, which was up 7143.44% from -$21.3 million recorded in Q3 2022.
- In the past 5 years, Atea Pharmaceuticals' Free Cash Flow ranged from a high of $318.5 million in Q4 2020 and a low of -$75.4 million during Q4 2021
- Over the past 3 years, Atea Pharmaceuticals' median Free Cash Flow value was -$17.1 million (recorded in 2021), while the average stood at $7.2 million.
- Over the last 5 years, Atea Pharmaceuticals' Free Cash Flow had its largest YoY gain of 33802.65% in 2021, and its largest YoY loss of 27349.16% in 2021.
- Quarter analysis of 3 years shows Atea Pharmaceuticals' Free Cash Flow stood at $318.5 million in 2020, then crashed by 123.68% to -$75.4 million in 2021, then surged by 71.43% to -$21.5 million in 2022.
- Its Free Cash Flow stands at -$21.5 million for Q4 2022, versus -$21.3 million for Q3 2022 and -$20.4 million for Q2 2022.